title: Invokamet and Xigduo XR: two new combinations for type 2 diabetes.
mesh_terms: D001559:Benzhydryl Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000068896:Canagliflozin; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D017277:Drug Approval; D005960:Glucosides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D051247:Sodium-Glucose Transport Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013876:Thiophenes / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014481:United States
chemical_list: D001559:Benzhydryl Compounds; D003692:Delayed-Action Preparations; D005960:Glucosides; D007004:Hypoglycemic Agents; D051247:Sodium-Glucose Transport Proteins; D013876:Thiophenes; D000068896:Canagliflozin; C529054:dapagliflozin